Insmed Incorporated (NASDAQ:INSM) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company eyes Brensocatib approval by August 12, and its TPIP Phase 3 and $750 million funding ...

Insmed Incorporated (NASDAQ:INSM) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company eyes Brensocatib approval by August 12, and its TPIP Phase 3 and $750 million funding bolsters ...

The company eyes Brensocatib approval by August 12, and its TPIP Phase 3 and $750 million funding bolsters pipeline momentum.

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis, chronic rhinosinusitis ...

The drug is currently being evaluated in Phase II clinical trial to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of ...

Insmed Incorporated (NASDAQ:INSM) holds a position among the list of 10 stocks with huge catalysts on the horizon. The company eyes Brensocatib approval by August 12, and its TPIP Phase 3 and $750 ...

Brensocatib: AstraZeneca Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis.

Shares rose after Phase 2 data for TPIP in PAH exceeded investor expectations. We are also positive on brensocatib for non-cystic fibrosis bronchiectasis, which is a $5 billion-plus opportunity.

We are also positive on brensocatib for non-cystic fibrosis bronchiectasis, which is a $5 billion-plus opportunity. Physician feedback and survey data suggests the drug could be transformative, ...